ClinicalTrials.gg
RecruitingNCT06276491Updated Oct 9, 2026

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

A Phase 1 interventional study of XmAb541 in Ovarian Cancer, Endometrial Cancer and Germ Cell Tumor, sponsored by Xencor, Inc.. Recruiting at 27 sites in 6 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 9, 2026First sites in France and United Kingdom8 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
282
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 277 open to participants now, 453 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
196th of 1,499
282 · median 47
Started
2024
with 78 others
Phase 1
548 of 1,780
74 open now
Primary completion
2027-12
later than 267 of 451 live
Registered
1,588th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 196th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 79 that started in 2024, is one of 548 in phase 1, reaches primary completion later than 267 of the 451 other live ones, and was the 1,588th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

277 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

272 more — sign in →

All 277 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

03

Conditions studied

  • Ovarian Cancer
  • Endometrial Cancer
  • Germ Cell Tumor
  • Testicular Germ Cell Tumor
  • Ovarian Germ Cell Tumor

Keywords

  • Phase 1
  • Ovarian Cancer
  • CLDN6
  • Testicular Cancer
  • Germ Cell Tumor
  • Endometrial Cancer
  • T-cell Engager
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years
  • CLDN6+ tumor
  • Histological or cytological documentation of locally advanced, recurrent, or ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma of the uterine corpus), GCT resistant to previous treatment
  • Adequate performance status
  • ≥ 3 months
  • Adequate liver, kidney, and bone marrow function

Key Exclusion Criteria:

  • Participants with untreated are excluded. Participants with treated brain metastases may participate, provided they are radiologically stable.
  • Active known or suspected disease
  • Have any condition requiring systemic treatment with , prednisone equivalents, or other medications within 14 days prior to first dose of study drug
  • cardiovascular, pulmonary or gastrointestinal disease
  • Active or
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    Dose escalation and Dose Expansion of XmAb541

    Intravenous or Subcutaneous administration

    Biological: XmAb541

Interventions

  • BiologicalXmAb541

    Monoclonal bispecific antibody

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: Day 1 to 2 years

  2. Incidence of dose-limiting toxicities (DLTs)

    Time frame: Day 1 to Day 28

  3. Incidence of cytokine release syndrome (CRS)

    Time frame: Day 1 to Day 28

Secondary outcomes

  1. Measurement of Cmax

    Peak plasma concentration

    Time frame: Day 1 to 2 years

  2. Measurement of area under curve (AUC)

    Area under the plasma concentration versus time curve

    Time frame: Day 1 to 1.4 years

  3. Measurement of Ctrough

    Plasma concentration before next dose

    Time frame: Day 1 to 2 years

  4. Objective Response Rate

    Objective Response Rate by RECIST 1.1 assessment of CT/MRI imaging

    Time frame: Day 1 to 2 years

  5. Duration of Response

    Duration of Response Objective Response Rate by RECIST 1.1 assessment of CT/MRI imaging

    Time frame: Day 1 to 2 years

  6. Changes in Circulating Tumor DNA (ctDNA)

    Maximum variant frequency or mean/median variant frequency

    Time frame: Day 1 to 4 months

07

Study locations

27 of 27 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2027, 44 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 44 months is close to that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Feb 26, 2024
StartActual
Apr 4, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 3 sites removed — first sites in France and United Kingdom
Show 8 added (3 United States, 2 Spain, 1 Belgium, 1 France, 1 United Kingdom)
  • Stanford University · Palo Alto, United States
  • University of California San Francisco · San Francisco, United States
  • The John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, United States
  • UZ Leuven · Leuven, Belgium
  • Centre Hospitalier Lyon-Sud · Pierre-Bénite, France
  • Clinical Universidad de Navarra · Madrid, Spain
  • Clinical Universidad de Navarra · Pamplona, Spain
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
Show 3 removed
  • Stanford · Palo Alto, United States
  • University of California · San Francisco, United States
  • The John Theruer Cancer Center at Hackensack University Medical Center · Hackensack, United States
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    8 sites added, 3 sites removed — first sites in France and United Kingdom
    Show 8 added (3 United States, 2 Spain, 1 Belgium, 1 France, 1 United Kingdom)
    • Stanford University · Palo Alto, United States
    • University of California San Francisco · San Francisco, United States
    • The John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, United States
    • UZ Leuven · Leuven, Belgium
    • Centre Hospitalier Lyon-Sud · Pierre-Bénite, France
    • Clinical Universidad de Navarra · Madrid, Spain
    • Clinical Universidad de Navarra · Pamplona, Spain
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    Show 3 removed
    • Stanford · Palo Alto, United States
    • University of California · San Francisco, United States
    • The John Theruer Cancer Center at Hackensack University Medical Center · Hackensack, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06276491
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Apr 4, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

XmAb541-01 Central Contact
Contact
info541-01@xencor.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion